Cord blood is the blood that remains in the umbilical cord after the delivery of a newborn. It is a rich source of stem cells and immune system cells. During cord blood banking, these cells are isolated and cryopreserved for future use. The cells are collected from the two arteries and the vein which run along the length of the umbilical cord. The Wharton’s jelly is a gelatinous tissue that composes the umbilical cord, which also contains valuable therapeutic cells such as MSCs. [Read more…]
How Induced Pluripotent Stem Cells (iPSCs) Are Changing The World As We Know It
Since their introduction in 2006, iPSCs (or induced pluripotent stem cells) have changed the way we research and treat diseases. In large part, this is thanks to bypassing the ethical concerns associated with embryonic stem cells.
So, why exactly is everyone talking about iPSC applications and their uses within medicine?
If you’re interested in the answer, we’ve made this guide to highlight the ways these stem cells are impacting a wide variety of industries. Let’s get started. [Read more…]
A Complete List of All Publicly Announced RMAT Designations (160)
To date, what number of U.S. FDA-approved RMATs have been issued and to whom have they been awarded?
The answer is that 160 RMAT (Regenerative Medicine Advanced Therapy) designations have been publicly announced by biotech and pharma companies. However, the FDA states it has received 388 requests and issued 193, which means that a handful are not yet public knowledge. Therefore, a few companies are operating in stealth mode with regard to their RMAT designations and approximately half of RMAT applications get approved (193 approvals / 388 applications = 49.7%).
Top Companies Developing Cell Therapy Treatments For Diabetes in 2026
Below is a list of the top companies exploring cell therapy treatments for diabetes.
In this article:
- Companies Exploring Stem Cell Treatment for Diabetes
- Seraxis | Cell Replacement Therapy for Type 1 Diabetes
- Sollagen | Diabetic Ulcers and Chronic Wounds
- Unicyte AG | Diabetes Cell Therapy
- ViaCyte | Insulin for Diabetes
- Sernova | Stem Cell for Diabetes Treatment
- Betalin Therapeutics | Insulin Production
- AltuCell | Stem Cell Therapy for Diabetes Type 2
- NextCell Pharma AB | Stem Cell Therapy for Diabetes Type 1
- Osiris Therapeutics | Type 1 Diabetes Control
- Mesoblast | Type 2 Diabetes Treatment
- Evotec and Sanofi | Stem Cell for Diabetes
- Orgenesis | Insulin-Producing Cells
- Semma Therapeutics | Type 1 Diabetes Therapy
- Novo Nordisk | Treatment of Type 1 Diabetes
- Beta-O2 | Artificial Pancreas for Diabetes
- Eli Lilly and Sigilon |Â Stem Cell for Diabetes
- Pharmacyte Biotech | Encapsulated Human Cells
- Vertex Pharmaceuticals | Stem Cell-Derived Insulin-Producing Cell Therapy
- Amarna Therapeutics | Investigational Gene Therapy
- Aspect Biosystems & Novo Nordisk| Implantable Bioprinted Tissues
- Adocia | doShell® Islets for Type 1 Diabetes
- NewcelX Ltd. | Stem Cell-Derived Islet Replacement for Type 1 Diabetes
Pivotal Trends Impacting the Global Cord Blood and Tissue Industry in 2026
The cord blood industry came into existence in the early 1990’s with the formation of several cord blood banks in the U.S. and worldwide. It has been 40 years since it was first proposed that stem and progenitor cells were present in human cord blood. [Read more…]